Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

Release Date: February 28, 2023

Expiration Date: February 28, 2024

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in metastatic castrate-sensitive prostate cancer (mCSPC) and castrate-resistant prostate cancer (mCRPC). In this educational program, these experts discuss unmet clinical needs in CSPC and CRPC, mechanisms of action of CDK4/6 inhibitors, and recent clinical trial data with these agents to inform physicians on practice-changing evidence to optimize care and survival outcomes for their patients.

This educational activity is an archive of the live satellite symposium held on February 17, 2023.

Target Audience

This educational program is directed toward medical oncologists, urologists, and other allied health care professionals interested in the treatment of prostate cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the pathophysiological mechanisms of CDK4/6 dysregulation in prostate cancer and rationale underlying their inhibition in advanced CSPC and CRPC
• Assess study design and clinical updates on CDK4/6 inhibitors investigated for the treatment of patients with advanced CSPC and CRPC
• Evaluate evidence from pivotal trials on CDK4/6 inhibitors within the context of evolving therapeutic strategies for patients with advanced prostate cancer
• Develop proactive strategies to monitor and mitigate adverse events associated with CDK4/6 inhibitors evaluated in patients with prostate cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.